CN116194112A - 表现出mnk抑制作用的吡啶-1,5-二酮及其使用方法 - Google Patents

表现出mnk抑制作用的吡啶-1,5-二酮及其使用方法 Download PDF

Info

Publication number
CN116194112A
CN116194112A CN202180056845.0A CN202180056845A CN116194112A CN 116194112 A CN116194112 A CN 116194112A CN 202180056845 A CN202180056845 A CN 202180056845A CN 116194112 A CN116194112 A CN 116194112A
Authority
CN
China
Prior art keywords
compound
group
alkyl
cycloalkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056845.0A
Other languages
English (en)
Chinese (zh)
Inventor
西奥多·J·普莱斯
詹姆斯·J·萨恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4e Treatment Co
Original Assignee
4e Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4e Treatment Co filed Critical 4e Treatment Co
Publication of CN116194112A publication Critical patent/CN116194112A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
CN202180056845.0A 2020-06-30 2021-06-30 表现出mnk抑制作用的吡啶-1,5-二酮及其使用方法 Pending CN116194112A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063046325P 2020-06-30 2020-06-30
US63/046,325 2020-06-30
PCT/US2021/039982 WO2022006331A2 (en) 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibitng mnk inhibition and their method of use

Publications (1)

Publication Number Publication Date
CN116194112A true CN116194112A (zh) 2023-05-30

Family

ID=79315594

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056845.0A Pending CN116194112A (zh) 2020-06-30 2021-06-30 表现出mnk抑制作用的吡啶-1,5-二酮及其使用方法

Country Status (11)

Country Link
US (1) US20230286983A1 (https=)
EP (1) EP4171565A4 (https=)
JP (1) JP2023533616A (https=)
KR (1) KR20230041715A (https=)
CN (1) CN116194112A (https=)
AU (1) AU2021300363A1 (https=)
BR (1) BR112022026275A2 (https=)
CA (1) CA3183551A1 (https=)
IL (1) IL299512A (https=)
MX (1) MX2022016516A (https=)
WO (1) WO2022006331A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3225747A1 (en) * 2021-06-30 2023-01-05 4E Therapeutics, Inc. Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
EP4646266A1 (en) * 2023-01-04 2025-11-12 4E Therapeutics, Inc. Solid state forms of mnk inhibitors
WO2026006417A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Formulations of mnk inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102858782A (zh) * 2010-02-26 2013-01-02 贝林格尔.英格海姆国际有限公司 用于药物组合物的具有Mnk1/Mnk2 抑制活性的4-[环烷基氧基(杂)芳基氨基]噻吩并[2,3-d]嘧啶
CN103874496A (zh) * 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
US20150376181A1 (en) * 2014-06-25 2015-12-31 Effector Therapeutics, Inc. Mnk inhibitors and methods related thereto
US20170121339A1 (en) * 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
CN108495855A (zh) * 2015-11-20 2018-09-04 生命弧度公司 作为mnk抑制剂的稠合噻唑并嘧啶衍生物
WO2018218038A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
CN110256432A (zh) * 2019-06-27 2019-09-20 诺沃斯达药业有限公司 抑制mnk1和mnk2的多环化合物
WO2020086713A1 (en) * 2018-10-24 2020-04-30 Effector Therapeutics, Inc. Crystalline forms of mnk inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2017068064A1 (en) * 2015-10-22 2017-04-27 Selvita S.A. Pyridone derivatives and their use as kinase inhibitors
WO2017165908A1 (en) * 2016-03-31 2017-10-05 South Australian Health And Medical Research Institute Limited Method of inhibiting high fat diet-related conditions
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
EP3972593B1 (en) * 2019-05-23 2025-07-02 Board of Regents, The University of Texas System Inhibitor of mnk for the treatment of neuropathic pain

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102858782A (zh) * 2010-02-26 2013-01-02 贝林格尔.英格海姆国际有限公司 用于药物组合物的具有Mnk1/Mnk2 抑制活性的4-[环烷基氧基(杂)芳基氨基]噻吩并[2,3-d]嘧啶
CN103874496A (zh) * 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
US20150376181A1 (en) * 2014-06-25 2015-12-31 Effector Therapeutics, Inc. Mnk inhibitors and methods related thereto
US20170121339A1 (en) * 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
CN108495855A (zh) * 2015-11-20 2018-09-04 生命弧度公司 作为mnk抑制剂的稠合噻唑并嘧啶衍生物
WO2018218038A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
WO2020086713A1 (en) * 2018-10-24 2020-04-30 Effector Therapeutics, Inc. Crystalline forms of mnk inhibitors
CN110256432A (zh) * 2019-06-27 2019-09-20 诺沃斯达药业有限公司 抑制mnk1和mnk2的多环化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIERS, STEPHANIE ET AL.: "Reversal of peripheral nerve injury-induced neuropathic pain and cognitive dysfunction via genetic and tomivosertib targeting of MNK", 《NEUROPSYCHOPHARMACOLOGY : OFFICIAL PUBLICATION OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY 》, vol. 45, no. 3, 7 October 2019 (2019-10-07), pages 524 - 533, XP036990703, DOI: 10.1038/s41386-019-0537-y *

Also Published As

Publication number Publication date
CA3183551A1 (en) 2022-01-06
WO2022006331A3 (en) 2022-02-10
EP4171565A2 (en) 2023-05-03
EP4171565A4 (en) 2024-11-27
US20230286983A1 (en) 2023-09-14
MX2022016516A (es) 2023-03-28
KR20230041715A (ko) 2023-03-24
WO2022006331A9 (en) 2022-03-03
JP2023533616A (ja) 2023-08-03
WO2022006331A8 (en) 2023-03-16
WO2022006331A2 (en) 2022-01-06
IL299512A (en) 2023-02-01
AU2021300363A1 (en) 2023-02-09
BR112022026275A2 (pt) 2023-03-14

Similar Documents

Publication Publication Date Title
US12110292B2 (en) Ligands to cereblon (CRBN)
KR102851010B1 (ko) 포스파티딜이노시톨 3-키나제 저해제
JP7796671B2 (ja) Ｎｅｋ７キナーゼの阻害剤
US12030892B2 (en) CRBN modulators
US20220127271A1 (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
US20250205244A1 (en) Methods of treating migraine with mnk inhibitors
CN116194112A (zh) 表现出mnk抑制作用的吡啶-1,5-二酮及其使用方法
US11479561B2 (en) Tetrahydroisoquinoline derivatives
JP2024525480A (ja) Ｍｎｋ阻害を示すスピロ環式ピリジン－１，５－ジオン及びその使用方法
WO2022159835A1 (en) Nek7 inhibitors
US20250177382A1 (en) Nek7 inhibitors
HK40060172B (en) Phosphatidylinositol 3-kinase inhibitors
HK40060172A (en) Phosphatidylinositol 3-kinase inhibitors
HK40034453B (zh) 嘧啶环己烯基糖皮质激素受体调节剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination